For primary hyperlipidemia. ANDA 208670, held by Bionpharma. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 208670 (Colesevelam Hydrochloride), held by Bionpharma, was first approved by FDA on Sep 13, 2019, with 2 approved supplements and 0 published complete response letters.
Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. reduce LDL-C levels in boys and post-menarchal girls, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification. improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Do not use for treatment of type 1 diabetes or for diabetic ketoacidosis. Not studied in Fredrickson Type I, III, IV, and V dyslipidemias. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 13, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colesevelam Hydrochloride625MG · tablet;oral | Colesevelam Hydrochloride | Rx |
| Apr 22, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 22, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 13, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters